amikacin in an inhaled form that perfectly targets Gram negative bacteria in the lungs will be the default treatment for pneumonia - Arikace should gain acceptance rapidly especially because of the speed of the healing action and reduced side effects from the efficient delivery assuming the price is right for the speedier healing versus other antibiotics. The area it won't become the default treatment is in pneumonia caused by anything other than bacteria like a virus since amikacin isn't an antiviral drug. In kids viral pneumonia is more common than from bacteria, in adults bacteria is the biggest cause. Older patients with kidney problems will probably be prescribed an antibiotic that is less harsh on the kidneys as well. But you're right that inhaled liposome antibiotics in general are looking very promising.
Or the 66 million shares shorted as of the 15th are starting to feel to the heat.
What is Iplex worth to Merck? Canaccord has a $12 target this year. Looks like $8 is on it's way before the Biotech conference.
what did you expect? daytime tv is designed for stay-at-home moms. I haven't seen it yet so I have no comment.
Access Hollywood segment on Lifeline in June.